Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Semin Cancer Biol. 2019 Dec 23;65:99–113. doi: 10.1016/j.semcancer.2019.12.019

Table 1.

Completed and ongoing clinical trials utilizing epigenetic modifiers in cancer.

Trial number Status Title Drug and Schedule Study Type Notes
NCT03812796 Recruiting Epigenetic Modulation of the immunE response in GastrointEstinal Cancers Phase IIA: Domatinostat in an oral tablet given at varying doses. Given Avelumab intravenously at 10 mg/kg every two weeks.
Phase IIB: Patients treated with domatinostat at safe combination dose found in phase IIA. Given Avelumab intravenously at 10 mg/kg every two weeks.		 Phase 2 GI cancer - microsatellite stable colorectal or gastroesophageal cancer
NCT02664181 Completed Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Pateients with NSCLC: Precise Trial Experimental: Oral THU (10 mg/kg) followed by oral decitabine (0.2 mg/kg) 60 minutes after THU occuring consectuively for two days weekly. Nibolumab adminstered at 3 mg/kg intravenously every two weeks until progression.
Active Comparator: Nivolumab 3 mg/kg intravenously every two weeks until progression.		 Phase 2

Lung Cancer, Non-small cell lung cancer
NCT02900560 Recruiting Study of Pembrolizumab With of Without CC-486 in Patients with Platinum-Resistance Ovarian Cancer Cohort 1: Oral Azacitidine (CC-486) at 100 mg once a day for 21 days and then 7 days off. Given with Pembrolizumab at 200 mg intravenously every 21 days.
Cohort 2: Oral Azacitidine (CC-486) at 100 mg twice a day for 21 days and then 7 days off. Given with Pembrolizumab at 200 mg intravenously every 21 days
Cohort 3: Oral Azacitidine (CC-486) at 300 mg once a day for 14 days and then 14 days off. Given with Pembrolizumab at 200 mg intravenously every 21 days.
Cohort 4: Oral Azacitidine (CC-486) at 300 mg once a day for 21 days and then 7 days off. Given with Pembrolizumab at 200 mg intravenously every 21 days.		 Phase 2

Epithelial Ovarian Cancer
NCT03206047 Suspended (Other-Pending Phase 2 Portion of Study) Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Cohort 1: Atezolizmab administered intravenously over 30–60 minutes on day 1 and 15. Treatment regimen repeats every 28 days for 24 courses.
Cohort 2: Guadecitabine administered subcutaneously on days 1–5. Treatment repeats every 28 days for up to 6 courses. Atezolizumab administered intravenously over 30–60 minutes on day 8 and day 22. Treatment regimen repeats every 28 days for up to 24 courses.
Cohort 3: Guadecitabine and Aztezolizumab administered in the same manner as cohort 2. Addition of CDX-1401 vaccine intravenously occurs on day 15 and poly ICLC subcutaneously on days 15 and 16. Treatment repeats every 28 days for up to 6 courses.		 Phase 1

Platinum-Resistant: Fallopian Tube Carcinoma, Ovarian Carcinoam, Primary Peritoneal Carcinoma

Recurrent: Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
NCT02951156 Active, Not recruiting Avelumab in Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients with Relapsed or Refractory Diffuse Large B cel Lymphoma Phase 1b (Arm A): Azelumab, Utomilumab, Rituzimab

Phase 1b (Arm B): Avelumab, Utomilumab, Azacitidine
Phase 1b (Arm C): Avelumab, Rituxima, Bendamustine
Phase 3 (Arm D): Selected regimen from Phase 1b component.
Phase 3 (Arm E): Choice of investigator to do either rituximad/bendamustine or rituximab/gemcitabine/oxaliplatin.		 Phase 3

Diffuse Large B-Cell Lymphoma
NCT03765229 Recruiting An Exploratory Study of Pembolizumab Plus Entinostat in Non-inflamed Stage III/IV Melanoma Entinostat at 5 mg administered orally occuring once weekly of a 21 day cycle starting on day 1 of study treatment; Pembrolizumab at 200 mg administered intravenously every 3 weeks starting at cycle 2 (occurs after research tumor biopsy at the end of cycle 1) Phase 2 Melanoma Combination therapy of both entionstat and pembrolizumab will continue if patient has clinical beenfit from therapy for up to 27 weeks.
NCT00387465 Completed Azacitidine and Entinostat in Treating Patients with Recurrent Advanced Non-Small Cell Lung Cancer Phase 1: Azacitidine at 30 mg/m2 administered subcutaneously. Entinostat at 7 mg orally on day 3 and 10 of each cycle.
Phase 1: Azacitidine at 40 mg/m2 administered subcutaneously. Entiostat at 7 mg orally on days 3 and 10 of each cycle.

Phase 2: Azacitidine at 40 mg/m2 administed subcutaneously on days 1–6 and 8–10. Entiostat at 7 mg administered orally on day 3 and 10. Treatment repeats every 28 days.		 Phase 1/ Phase 2

Recurrent Non-small Cell Lung Cancer, Stage IIIA NSCLC, Stage IIIB NSCLC, Stage IV NSCLC
NCT02437136 Active, Not recruiting Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC with Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer Cohort 1: Ph 2 NSCLC (squamous or adeno). Patients not pre-treated with PD-1 or PD-L1 blocking antibody. Given entinostat and pembrolizumab

Cohort 2: Ph 2 NSCLC. Patients pre-treated with PD-1/PD-L1 blocking antibody. Given entinostat and pembrolizumab.
Cohort 3: Ph 2 Melanoma. Patients pre-treated with PD-1/PD-L1 blocking antibody. Given entinostat and pembrolizumab.
Cohort 4: Ph 2 Mismatch Repair-Proficient CRC. Patients not pre-treated with PD-1 or PD-L1 blocking antibody. Given entiostat and pembrolizumab.		 Phase 1/Phase 2 Non-small Cell Lung Cancer, Melanoma, Mismath Repair-Proficient Colorectal Cancer
NCT02936752 Recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrom After DMNTi Therapy Failure Patients receive low dose of oral entinostat on days 1 and 8 or a higher dose on days 1, 8, and 15. Pembrolizumab given intravenously over 30 minutes on day 1 of courses 2 and courses after. Treatment repeats every 21 days for up to 4 courses. Phase 1
Blasts 21–20 Percent of bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Previously treated Myelodysplastic syndrome
NCT02546986 Active, Not recruiting Safety and Efficacy Study of CC-486 with MK-3475 to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer Experimental Arm: Patients receive oral Azacitidine at 300 mg daily on days 1–14 of the 21 day cycles. Pembrolizumab adminstered intravenously for 30 minnutes on day 1 of the 21 day cycles.
Control Arm: Patients receive pembrolizumab intravenously for 30 minutes on day 1 of the 21 day cycles. Oral placebo will be adminstered on days 1–14 of the 21 day cycles.		 Phase 2

Non-small Cell Lung Carcinoma
NCT02909452 Active, Not recruiting Continuation Study of Entinostat in Combination with Pembrolizumab in Patients with Advanced Solid tumors Entinostat at 1 mg given daily with pembrolizumab given every three weeks.

Entinostat at 5 mg given once weekly with pembrolizumab given every three weeks.

Entinostat at 10 mg given bi-weekly with pembrolizumab given every three weeks.		 Phase 1 Neoplasms (Glandular and Epithelial), Neoplasms by histologic type, brnchial neoplasms, lung neoplasms, respiratory tract neoplams, thoracic neoplasms, digestive system neoplasms, endocrine gland neoplasms, NSCLC, lung diseases, breast disease, renal neoplasm, solid tumors
NCT02697630 Active, Not recruiting Efficacy Study of Pembrolizumab with Entinostat to Treat Metastatic Melanoma of the Eye (PEMDAC) Pembrolizumab at 200 mg adminstered intravenoulsy every third week. Entinostat at 5 mg administered orally once weekly. Phase 2 Metastatic Uveal Melanoma
NCT02538510 Active, Not recruiting Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous cell Head and Neck Cancer or Salivary Gland Cancer that is Metastatic and/or Cannot be removed by surgery Receive vorinostat orally or via PEG on days 1–5 and pembrolizumab intravenously over 30 minutes on day 1. Treatment courses repeat every 21 days for up to 2 years Phase 1/Phase 2 Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent salivary Gland Carcinoma, Squamous Cell Carcinoma Metastatic in Neck with Occult primary, Stage III Major salivary Gland carcinoma, Stage III nasal cavity and paranasal sinus squamous cell carcinoma, Stage III nasopharynheal carcinoma, Stage IV nasopharyngeal carcinoma, Stage IVA major salivary gland carcinoma, Stage IVA nasal cvity and paranasal sinus squamous cell carcinoma, Stage IVB major salivary gland carcinoma, Stage IVB Nasal cavity and Paranasal sinus squamous cell Carcinoma, Stage IVC major salivary gland carcinoma, Stage IVC nasal cavity and Paranasal sinus Squamous cell carcinoma
NCT02638090 Recruiting Pembro and Vorinostat for Patients with Stage IV Non-small Cell Lung Cancer (NSCLC) Phase 1 (Dose Escalation): Level 1 - Vorinostat at 200 mg given orally daily with pembrolizumab at 200 mg adminstered intravenously every 3 weeks. Level 2 - Vorinostat at 400 mg given orally daily with pembrolizumab at 200 mg adminstered intravenously every 3 weeks.
Phase 1b (Expansion): Level 1-Pembrolizumab plus vorinostat given at maximum tolerated dose.
Arm A: Pembrolizumab adminstered at 200 mg intravenously every 3 weeks.
Arm B: Pembrolizumab plus vorinostat treatment given at maximum tolerated dose.		 Phase 1/Phase 2

Lung cancer, Non-small Cell Lung Cancer
NCT02619253 Recruiting Phase I/Ib study of Pembrolizumab with Vorinostat for Patients with Adavanced Renal or Urothelial Cell Carcinoma Dose Finding cohort: Patients will be given oral vorinostat daily for 14 days with pembrolizumab at 200 mg intravenously. Two doses of vorinostat will be tested 100 and 200 mg. Each cycle is every 21 days.
Expansion Cohort: After determining which dose of vorinostat should be used in the dose finding cohort, patients with prior treatments are enroleed in three different cohorts. 15 anti-PD1 naive renal and urothelial patients, 15 anti-PD1 resistane renal and urothelial pateitns and 15 patients with androgen-sensitive or castration-resistance prostate cancer. Each cohort will then receive the established vorinostat dose along with 200 mg pembrolizumab intravenously.		 Phase 1

Renal Cell Carcinoma, Urinary Bladder Neoplasms
NCT02901899 Recruiting Guadecitabine and Pembrolizumab in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian tube Cancer Patients receive guadecitabine subcutaneously on days 1–4 and pembrolizumab intravenously over 30 minutes on day 5. Treatment courses repeat evry 21 days. Phase 2

Recurrent - Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
NCT02512172 Active, Not recruiting A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer Patients given oral azacitidine at 300 mg on days 1–14 or 21 for every 28 days. Given pembrolizumab at 200 mg intravenously on days 1 and 15 every 28 days
Patients given Romidepsin at 14 mg/m2 on days 1,8, and 15. Given pembrolizumab at 200 mg intravenously on days 1 and 15 every 28 days.
Patients given oral azacitidine at 300 mg on days 1–14 or 21 and romidepsin at 7 mg/m2 on days 1,8 and 15. Given pemrbolizumab at 200 mg intravenously on days 1 and 15 every 28 days.		 Phase 1

Colorectal Cancer		 Romidepsin - Chemotherapy drug approved by FDA for treatment of cutaneous T-cell lymphoma
NCT02260440 Active, Not recruiting A Phase 2 Study of Pembrolizmab (MK-3475) in Cominaiton with Azacitidine in Subjects With Chemorefractory Metastatic Colorectal Cancer Pembrolizumab given at 200 mg every 21 days. Azacitidine given at 100 mg daily subcutaneously on days 1–5 every 21 days. 9 cycles of treatment. Phase 2
Colorectal Cancer
NCT02845297 Recruiting Study of Azacitidine in Combination with Pembrolizumad in Replased/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (>= 65 years) AML Patients Cohort 1 (Safety Run in Phase) : Treatment of relapsed and refractory AML Patients. Given pembrolizumab intravenously and azacitadine intravvenoulsy or subcutaneously.

Cohort 2: Treatment of newly diagnost AML patients (>= 65 years). Given pembrolizumab intravenously and azacitadine intravenously or subcutaneously.		 Phase 2

Acute Myeloid Leukemia
NCT02816021 Recruiting Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma Arm A - Metastatic Melanoma PD-1 Naive: 3 week treatment cycles. Oral azacitidine given for days 1–15 of every cycle. Pemrbolizumab administered intravenously every 3 weeks and after the oral dose of azacitidine on concurrent treatment days.
Arm B - Metastatic Melanoma Post PD-1 Progression: 3 week treatment cycles. Oral azacitidine given for days 1–15 of every cycle. Pembrolizumab adminstered intravenously every 3 weeks and after oral dose of azacitidine on concurrent treatment days.		 Phase 2

Melanoma and other malignant neoplasms of skin, metastatic melanoma
NCT01928576 Recruiting Phase II Anti-PD1 Epigentic Therapy Study in NSCLC Arm C: Nivolumab at 3 mg/kg given every 2 weeks until disease progression.
Arm D: Treatment occurs every 28 days for 6 cycles. Azacitidine given at 40 mg.m2 on days 1–5 and days 8–10. Entinostat at 5 mg given on days 3 and 10. Nivolumab given at 3 mg/kg on days 1 and 15. Followed by nivolumab at 3 mg/kg given every 2 weeks until disease progression.		 Phase 2

Non-small Cell Lung Cancer
NCT02397720 Recruiting Nivolumab and Azacitidine with or without Ipilimumab in Treating Patients with Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Arm I: Azacitidine adminstered intravenously over 1 hours or subcutaneously on days 1–7 or days 1–4 and days 7–9. Received nivolumab intravenously over 60 minutes on days 1 and 14 (courses 1–4) or on day 1 (course 5 and the courses following). Treatment courses repeat every 28 days.

Arm II: Receive azacitidine and nivolumab as in Arm I. Receive ipilimumab intravenously over 90 minutes on day 1 and then every 6 or 12 weeks.		 Phase 2 Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia arising from previous myelodysplastic syndrome, chronic myelomonocytic leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia, refractory acute myeloid leukemia, secondary acute myeloid leukemia, therapy-related actue myeloid leukemia
NCT02599649 Completed Lirilumab and Nivolumab with 5-Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Low or Intermediate-1 MDS Group: Lirilumab adminstered at 3 mg/kg intravenously over 60 minutes one time during every 28 day cycle.
Low or Intermediate-MDS Group: Nivolumab adminstered at 3 mg/kg intravenously over 60 minutes every 2 weeks during cycles 1–8. Lirilumab adminstered at 3 mg/kg intravenously over 60 minutes one time during every 28 day cycle.
High Risk MDS Group: Azacitidine adminstered at 75 mg/m2 intravenously over 60 minutes on days 1–7 of the 28 day cycle. Lirilumab adminstered at 3 mg/kg intravenously over 60 minutes on day 7 of each cycle.
High Risk MDS Group: Azacitidine adminstered at 75 mg/m2 intravenously over 60 minutes on days 1–7 of each 28 day cycle. Lirilumab adminstered at 3 mg/kg intravenously over 60 minutes on day 7 of each cycle. On days 7 and 21 of cycles 1–9 nivolumab is adminstered at 3 mg/kg intravenously over 60 minutes. On day 7 of cycle 10 and beyond, nivolumab adminstered intravenously over 60 minutes.		 Phase 2

Leukemia
NCT02530463 Recruiting Nivolumab and Ipilimumab with 5-azacitidine in Patients with Myelodysplastic Syndromes (MDS) Cohort 1 (Hypomethylating failure MDS cohort): Nivolumab adminstered intravenously at 3 mg/kg every 2 weeks for 6 cycles. After 6 cycles, use of Azacitidine is permitted to test concept of re-sensitization.
Cohort 2 (Hypomethylating failure MDS cohort): Ipilimumab adminstered intravenously at 3 mg/kg every 3 weeks for 6 cycles. After 6 cycles, use of Azacitidine is permitted to test concept of re-sensitization.
Cohort 3 (Hypomethylating failure MDS cohort): Nivolumab adminstered intravenously at 3 mg/kg on days 1 and 15. Ipilimumab adminstered intravenously at 3 mg/kg on day 1. After 6 cycles, use of Azacitidine is permitted to test concept of re-sensitization.
Cohort 4 (Previously untreated MDS cohort): Azacitidine admintered intravenously at 75 mg/m2 for 5 days every 4 weeks. On day 6 nivolumab adminstered intravenously at 3 mg/kg every 2 weeks.
Cohort 5 (Previously untreated MDS cohort): Azacitidine adminstered intravenously at 75mg/m2 for 5 days every 4 weeks. On day 6 ipilimumab adminstered intravenously at 3 mg/kg every 4 weeks.
Cohort 6 (Previously untreated MDS cohort): Azacitidine adminstered intravenously at 75 mg/m2 for 5 days every 4 weeks. On day 6 and day 20 nivolumab adminstered intravenously at 3 mg/kg and ipilimumab adminstered on day 6 intravenously at 3 mg/kg.		 Phase 2

Leukemia, Myelodysplastic syndrome
NCT02635061 Recruiting Selective HDAC6 Inhibitor ACY 241 in Combination with Nivolumab in Pateitns with Unresectabe Non-smell Cell Lung Cancer ACY-241 adminstered in combination with nivolumab. Phase 1
Non-small Cell Lung Cancer
NCT02890329 Recruting Ipilimumab and Decitabine in Treating Patients with Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Arm A (Post allo-HCT): Priming phase - patients are administered decitabine intravenously over 60 mintes on days 1–5 out of 28 days. Induction phase - patients are adminstered decatibine intravenously over 60 minutes on days 1–5 and ipilimumab is adminstered intravenously over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles. Maintenance phase - patients adminstered decitibine intravenously over 60 minutes on days 1–5 and ipilimumab is adminstered intravenously over 90 minutes on day 1. Treatment repeats every 4–8 weeks for up to 4 cycles.

Arm B (Transplant naive Patients): Priming phase - patients are adminstered decitabine intravenously over 60 mintes on days 1–5 out of 28 days. Induction phase - patients are adminstered decitabine intravenously over 60 minutes on days 1–5 and ipilimumab is adminstered intravenously over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles. Maintenance phase - patients are adminstered decitabine intravenously ver 60 minutes on days 1–5 and ipilimumab is adminstered intravenously over 90 minutes on day 1. Treatment repeats every 4–8 weeks for up to 4 cycles.		 Phase 1 Blasts 5% of more of bone marro nucleated cells, hemtopoietic cell transplant recipient, myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent acute myeloid leukemia with myelodysplasia-related changes, refractory acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia
NCT02608437 Unknown A Study Investigating SGI-110 in Combination with Ipilimumab in Unresectable or Metastatic Melanoma Patients (NIBIT-M4) SGI-110 administered at 30 mg/m2 subcutaneously on days 1–5 for 2 day cycles. Ipilimmab adminstered at 3 mg/kg intravenously over 90 minutes every 3 weeks for 4 cycles. Phase 1

Metastatic Melanoma
NCT02032810 Active, Not recruiting Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat with Ipilimumab with Unresectable III/IV Melanoma Patients assigned a dose of panobinostat (5, 10, 15, 20 mg). Dose depends on time point patients enters study. Patients given ipilimumab at 3 mg/kg. Phase 1
Skin Cancer, Melanoma
NCT02508870 Suspended A study of Atezolizumab Adminstered Alone or in Combination with Azacitidine in Participants with Myelodysplastic Syndromes Cohort A (HMA R/R MDS): Patients adminstered atezolizumab at 1200 mg intravenously every 3 weeks (21 day cycles) Treatment will continue for up to 17 cycles.
Cohort B (HMA R/R MDS): Induction - Patients adminstered atezolizumab at 840 mg intravenously on days 8 and 22 of 28 day cycles. Azacitidine adminstered at 75 mg/m2 subcutaneously on days 1–7 of 28 day cycles for 6 cycles. Maintenance - Patients who completed induction treatment will be adminstered atezolizumab at 1200 mg intravenously Q3W (21 day cycles) for up to 8 additional cycles.
Cohort C1 (HMA Naive MDS): Patients adminstered atezolizumab at 840 mg intravenously on days 8 and 22 of 28 day cycles. Azacitidine adminstered at 75 mg/m2 subcutaneously on days 1–7 of 28 day cycles.
Cohort C2 (HMA Naive MDS): Patients enrolled in Cohort C1 fulfil dose limiting toxicity, additional patients will be adminstered atezolizumab at 840 mg intravenously on days 8 and 22 of 28 day cycles. Azacitidine admintered at 75 mg/m2 subcutaneously on days 1–7 of 28 day cycles.
Cohort A2 (HMA R/R MDS): If atezolizumab alone or in combination with azacitidine is safe and tolerable. Patients will be randomly assigned to be adminstered atezolizumab at 1200 mg intravenously Q3W (21 day cycle) Treatment will continue up to 17 cycles.
Cohort B2 (HMA R/R MDS): If atezolizumab alone or in combination with azacitidine is safe and tolerable, patients will be randomly assigned to be administered atezolizumab at 840 mg intravenously on days 8 and 22 of each 28 day cycles and azacitidine admininistered at 75 mg/m2 subcutaneously on days 1–7 of 28 day cycles for 6 cycles during inducation. Patients who complete induction treatment with be adminstered atezolizumab at 1200 mg intravenously Q3W (21 day cycle) for up to 8 cycles.		 Phase 1

Myelodysplastic syndromes
NCT02708680 Active, Not recruiting Randomized Phase 2 study of Atezolizumab and Entinostat in pateitns with aTN Breast Cancer with Phase 1b Lead In Active Comparator: Entinostat given orally at RP2D in combination with atezolizumab.
Placebo Comparator: Placebo given orally in ocmbination with atezolizumab.		 Phase 1

Breast Cancer
NCT02117219 Completed Phase 1 Study to Evaluate MEDI4736 in Subjects with Myelodysplastic Syndrome Patients adminstered durvalumab intravenously. Azacitidine will be adminstered subcutaneously in combination with durvalumab. Tremelimumab adminstered intravenously. Durvalumab adminstered intravenously in combination with tremelilmumab. Patients adminstered durvalumab intravenously. Tremelimumab adminstered intravenously. Azacitidine will be adminstered subcutaneously in combination with durvalumab and tremelimumab. Phase 1

Myelodysplastic Syndrome
NCT02775903 Active, Not recruiting An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination with Durvalumab(MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (DS) or in Eldery Subjects with Acute Myeloid Leukemia (AML) Experimental: Azacitidine adminstered at 75 mg/m2 subcutaneously for 7 days every 4 weeks. Durvalmab adminstered intravenously at 1500 mg on day 1 every 4 weeks.
Active Comparator: Azacitidine adminstered at 75 mg/m2 subcutaneously every 7 days for 4 weeks.		 Phase 2
Acute Myeloid Leukemia, Myelodysplastic Syndromes
NCT02805660 Active, Not recruiting Phase 1/2 Study of Mocetinostat and Durvalumab in Patients with Advanced Solid Tumors and NSCLC Mocetinostat adminstered orally three times weekly. Durvalumab adminstered at 1500 mg intravenously in 28 day cycles with mocetinostat. Phase 1/ Phase 2
Advanced Cancer
NCT02915523 Active, Not recruiting Phase 1b/2 Study of Avelumab with or without Entinostat in Patietns with Advanced Epithelial Ovarian Cancer Active Comparator: Avelumab adminstered intravenously on day 1 of each 14 day cycle. Entinostat adminstered on day 1 and day 8 of each cycle at maxium tolerated does (MTD)/ RP2D determined in phase 1b part of study.
Placebo Comparator: Avelumab adminstered intravenously on day 1 of each 14 day cycle. Placebo adminstered on day 1 and day 8 of each cycle.		 Phase 1/ Phase 2

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer